- Home
- PAVM vs COCH Comparison
PAVM vs COCH Comparison
Compare PAVM & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAVM | COCH |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | 41 | 47 |
| Industry | Medical/Dental Instruments | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.5M | 47.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PAVM | COCH |
|---|---|---|
| Price | $9.10 | $0.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $65.00 | $6.00 |
| AVG Volume (30 Days) | 9.8K | ★ 172.9K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $603.94 | $1.58 |
| Revenue Next Year | $33.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.36 |
| 52 Week High | $28.44 | $1.91 |
Technical Indicators
Market Signals| Indicator | PAVM | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 54.31 |
| Support Level | $9.05 | $0.64 |
| Resistance Level | $9.26 | $0.73 |
| Average True Range (ATR) | 0.37 | 0.05 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 8.40 | 80.99 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.